NYSE: EVMN · Life Sciences · 7 alerts · CIK 2044725
Share price
$7.10Close, Nov 16
Market cap
$294M
Shares outstanding
41.35MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Evommune, Inc. filings on SEC EDGAR ↗
Evommune Licensing Deal with Hinova Pharmaceuticals Inc.
Evommune announced it has entered into an exclusive license agreement with Hinova Pharmaceuticals for EVO570, an oral VAV1-directed molecular glue degrader. Evommune acquired worldwide rights (excluding Greater China) to develop, manufacture, and commercialize the candidate, which it plans to develop for rheumatoid arthritis.
Evommune Licensing Deal with Hinova Pharmaceuticals Inc. Worth $30M
Evommune has entered into an exclusive license agreement with Hinova Pharmaceuticals to develop and commercialize EVO570, a VAV1 molecular glue degrader, globally excluding Greater China. Evommune will pay $20 million upfront in cash and $10 million in pre-funded warrants, with Hinova eligible for up to $1.07 billion in additional milestone payments plus tiered royalties.